• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

物理因素对经动脉化疗栓塞联合放疗治疗巨大肝细胞癌的影响。

The impacts of physical factors on huge hepatocellular carcinoma treated by transarterial chemoembolization combined with radiotherapy.

作者信息

Shen Juanjuan, Zhong Nanbao, Chen Zhonghua, Ma Danyu, Lin Jianhai

机构信息

Department of Tumor Radiotherapy, 900th Hospital of PLA, Fuzhou, China.

出版信息

Future Oncol. 2025 Jun;21(13):1687-1697. doi: 10.1080/14796694.2024.2395801. Epub 2024 Sep 12.

DOI:10.1080/14796694.2024.2395801
PMID:39263953
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12140484/
Abstract

To assess the influence of various physical factors on the outcome of transarterial chemoembolization combined with γ-ray hypofractionated radiation therapy (TACE-γHRT) for unresectable huge (≥10 cm) hepatocellular carcinoma (UH-HCC) patients. A total of 162 UH-HCC patients with different tumor locations treated with TACE-γHRT and a retrospective analysis was conducted to evaluate the impacts of selected physical parameters on clinical outcomes. The selected physical factors influenced the clinical outcomes significantly. No adverse events exceeding grade 3 were observed in the enrolled patients. Higher P and marginal dose, smaller tumor size and tumor location of neither skin nor gastrointestinal tracts involved were independent predictors for better overall survival and progression free survival.

摘要

为评估各种物理因素对不可切除的巨大（≥10厘米）肝细胞癌（UH-HCC）患者经动脉化疗栓塞联合γ射线低分割放射治疗（TACE-γHRT）疗效的影响。共有162例不同肿瘤部位的UH-HCC患者接受了TACE-γHRT治疗，并进行回顾性分析以评估所选物理参数对临床结局的影响。所选物理因素对临床结局有显著影响。在入组患者中未观察到超过3级的不良事件。较高的P值和边缘剂量、较小的肿瘤大小以及肿瘤位于既不涉及皮肤也不涉及胃肠道的部位是总生存期和无进展生存期较好的独立预测因素。

相似文献

1
The impacts of physical factors on huge hepatocellular carcinoma treated by transarterial chemoembolization combined with radiotherapy.物理因素对经动脉化疗栓塞联合放疗治疗巨大肝细胞癌的影响。
Future Oncol. 2025 Jun;21(13):1687-1697. doi: 10.1080/14796694.2024.2395801. Epub 2024 Sep 12.
2
Efficacy and safety of TACE combined with lenvatinib and PD-1 Inhibitor in intermediate-stage HCC exceeding the up-7 criteria: a retrospective cohort study.经动脉化疗栓塞术联合乐伐替尼和程序性死亡受体1抑制剂治疗超过up-7标准的中期肝细胞癌的疗效与安全性：一项回顾性队列研究
Front Immunol. 2025 Jun 12;16:1560750. doi: 10.3389/fimmu.2025.1560750. eCollection 2025.
3
Efficacy and safety of radiotherapy versus transarterial chemoembolization in combination with lenvatinib and camrelizumab for hepatocellular carcinoma with inferior vena cava/right atrium tumor thrombus: a multicenter study.放射治疗与经动脉化疗栓塞联合乐伐替尼和卡瑞利珠单抗治疗伴有下腔静脉/右心房肿瘤血栓的肝细胞癌的疗效和安全性：一项多中心研究
Hepatol Int. 2025 Mar 26. doi: 10.1007/s12072-025-10794-7.
4
Transarterial Chemoembolization With or Without Systemic Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Comparative Study.经动脉化疗栓塞联合或不联合全身治疗不可切除肝细胞癌的回顾性比较研究
Cancer Med. 2025 Feb;14(3):e70633. doi: 10.1002/cam4.70633.
5
Transarterial chemoembolization plus apatinib for unresectable hepatocellular carcinoma: a multicenter, randomized, open-label, phase III trial.经动脉化疗栓塞术联合阿帕替尼治疗不可切除肝细胞癌：一项多中心、随机、开放标签的III期试验
BMC Med. 2025 May 28;23(1):313. doi: 10.1186/s12916-025-04159-y.
6
Sintilimab plus lenvatinib in combination with transarterial chemoembolization and subsequent radiofrequency ablation for unresectable hepatocellular carcinoma: a single-arm, single-center study.信迪利单抗联合仑伐替尼与经动脉化疗栓塞及后续射频消融治疗不可切除肝细胞癌：一项单臂、单中心研究。
Sci Rep. 2025 Jul 25;15(1):27123. doi: 10.1038/s41598-025-12858-y.
7
Grading risk of microvascular invasion impacts survival in hepatocellular carcinoma patients undergoing adjuvant transarterial chemoembolization: A multicenter study.微血管侵犯分级对接受辅助性经动脉化疗栓塞的肝细胞癌患者的生存有影响：一项多中心研究。
Eur J Surg Oncol. 2025 Apr 24;51(8):110102. doi: 10.1016/j.ejso.2025.110102.
8
Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages.多中心回顾性GUIDANCE001研究：比较经动脉化疗栓塞联合或不联合酪氨酸激酶和免疫检查点抑制剂作为转化治疗手段治疗不可切除肝细胞癌的疗效——中期或晚期而非早期阶段存在生存获益
Hepatology. 2025 Aug 1;82(2):357-369. doi: 10.1097/HEP.0000000000001229. Epub 2025 Jan 15.
9
Survival in Patients With Recurrent Intermediate-Stage Hepatocellular Carcinoma: Sorafenib Plus TACE vs TACE Alone Randomized Clinical Trial.索拉非尼联合 TACE 与单纯 TACE 治疗复发性中期肝细胞癌患者的生存：随机临床试验。
JAMA Oncol. 2024 Aug 1;10(8):1047-1054. doi: 10.1001/jamaoncol.2024.1831.
10
Postoperative adjuvant transarterial chemoembolization prolongs overall survival in alpha-fetoprotein-negative hepatocellular carcinoma with bile duct tumor thrombosis: a long-term retrospective cohort study.术后辅助性经动脉化疗栓塞术可延长伴有胆管癌栓的甲胎蛋白阴性肝细胞癌患者的总生存期：一项长期回顾性队列研究
World J Surg Oncol. 2025 Jul 2;23(1):260. doi: 10.1186/s12957-025-03917-9.

本文引用的文献

1
Single-center analysis of percutaneous ablation in the treatment of hepatocellular carcinoma: long-term outcomes of a 7-year experience.单中心分析经皮消融治疗肝细胞癌：7 年经验的长期结果。
Abdom Radiol (NY). 2023 Mar;48(3):1173-1180. doi: 10.1007/s00261-023-03819-y. Epub 2023 Jan 30.
2
Outcomes of liver resection for huge hepatocellular carcinoma exceeding 10 cm in size: A single center experience.10cm 以上巨大肝细胞癌行肝切除术的疗效：单中心经验。
Am J Surg. 2023 Jun;225(6):1013-1021. doi: 10.1016/j.amjsurg.2022.12.005. Epub 2022 Dec 7.
3
Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma.立体定向体部放疗序贯纳武利尤单抗联合伊匹单抗或纳武利尤单抗治疗不可切除/晚期肝细胞癌的 1 期随机试验。
Int J Radiat Oncol Biol Phys. 2023 Jan 1;115(1):202-213. doi: 10.1016/j.ijrobp.2022.09.052. Epub 2022 Sep 13.
4
The effect of adjuvant transarterial chemoembolization for hepatocellular carcinoma after liver resection based on risk stratification.基于风险分层的肝癌切除术后辅助经动脉化疗栓塞的效果。
Hepatobiliary Pancreat Dis Int. 2023 Oct;22(5):482-489. doi: 10.1016/j.hbpd.2022.07.007. Epub 2022 Jul 30.
5
Combination Transarterial Chemoembolization and Stereotactic Body Radiation Therapy for Unresectable Single Large Hepatocellular Carcinoma: Results From a Prospective Phase 2 Trial.联合经动脉化疗栓塞和立体定向体部放疗治疗不可切除的单发大肝癌：一项前瞻性 2 期试验结果。
Int J Radiat Oncol Biol Phys. 2022 Oct 1;114(2):221-230. doi: 10.1016/j.ijrobp.2022.05.021. Epub 2022 May 26.
6
Liver resection for large and huge hepatocellular carcinoma: Predictors of failure, recurrence patterns, and prognoses.大肝癌和巨大肝癌的肝切除术：失败的预测因素、复发模式及预后
Asia Pac J Clin Oncol. 2023 Apr;19(2):e60-e70. doi: 10.1111/ajco.13777. Epub 2022 Apr 11.
7
Comparison of clinical outcome between stereotactic body radiotherapy and radiofrequency ablation for unresectable hepatocellular carcinoma.立体定向体部放疗与射频消融治疗不可切除肝细胞癌的临床疗效比较。
Medicine (Baltimore). 2022 Jan 28;101(4):e28545. doi: 10.1097/MD.0000000000028545.
8
Hepatic Resection Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: A Cohort Study.肝切除术与经动脉化疗栓塞术治疗中期肝细胞癌的队列研究
Front Oncol. 2021 Oct 27;11:618937. doi: 10.3389/fonc.2021.618937. eCollection 2021.
9
Development and validation of prognostic nomograms for single large and huge hepatocellular carcinoma after curative resection.根治性切除术后单个大肝癌和巨大肝癌的预后列线图的建立和验证。
Eur J Cancer. 2021 Sep;155:85-96. doi: 10.1016/j.ejca.2021.07.009. Epub 2021 Aug 6.
10
Treatment outcomes of stereotactic body radiation therapy using a real-time tumor-tracking radiotherapy system for hepatocellular carcinomas.使用实时肿瘤追踪放射治疗系统的立体定向体部放射治疗对肝细胞癌的治疗效果。
Hepatol Res. 2021 Aug;51(8):870-879. doi: 10.1111/hepr.13649. Epub 2021 May 11.